By Rahul Koul
“ We expect an uptake in volumes from FY25 due to the CDMO deals ”
Dr Satish Wagh , Chairman & Managing Director , Supriya Lifescience takes us through the company ’ s milestones , expansion plans , key R & D projects and focus on sustainability
By Rahul Koul
BioTech
Please provide an overview of Supriya Lifescience journey and growth in the Indian market since its inception . Key milestones that have shaped the company ' s direction ?
Supriya Lifescience has a wellestablished presence in API Manufacturing with focus in products of various therapeutic segments like – Antihistamine , Anti-Allergics , Vitamins , Anaesthetics , Anti- Asthmatics etc . Our commitment lies in setting the products , processes , and the systems as per the industry standards and in making continuous improvement to deliver quality products . Operating across 86 countries with over 1200 customers , our major revenue contributors are Asia and Europe , trailed by Latin America and North America .
With 14 active USDMFs , 8 active CEPs & World wide compliant facilities ( EMA , US FDA , WHO , PMDA , TGA , KFDA , ANVISA ), we thrive on strong backward integration model that boosts profit margins and supply chain security . Our high investment in R & D fosters a robust product portfolio
BIOVOICENEWS . COM 53